Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
B. KAYE*C. J. BREARLEY, N. J. CUSSANS, M. HERRON, M. J. HUMPHREY & A. R. MOLLATT. (1997) Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica 27:10, pages 1091-1102.
Read now
Read now
K. Dickstein, T. Aarsland, L. Woie, D. Kremer & A.M. Abrahamsen. (1984) Acute Hemodynamic and Hormonal Effects of Mk-521 in Congestive Heart Failure. Scandinavian Journal of Urology and Nephrology 18:sup79, pages 125-127.
Read now
Read now
C. I. Johnston, B. Jackson, R. Cubela & L. Arnolda. (1984) Mechanism for Hypotensive Action of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension. Part A: Theory and Practice 6:1-2, pages 551-561.
Read now
Read now
Articles from other publishers (55)
David J. Ponting, Krista L. Dobo, Michelle O. Kenyon & Amit S. Kalgutkar. (2022)
Strategies for Assessing Acceptable Intakes for Novel
N
-Nitrosamines Derived from Active Pharmaceutical Ingredients
. Journal of Medicinal Chemistry 65:23, pages 15584-15607.
Crossref
Crossref
Donald J. AbrahamPaul W. Erhardt, Rahul Khupse, Jeffrey G. Sarver & Brian J. Kress. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
105
.
Nori J.L. Smeets, Michiel F. Schreuder, Michiel Dalinghaus, Christoph Male, Florian B. Lagler, Jennifer Walsh, Stephanie Laer & Saskia N. de Wildt. (2020) Pharmacology of enalapril in children: a review. Drug Discovery Today 25:11, pages 1957-1970.
Crossref
Crossref
Akolade R. Oladipupo. (2020) Toxin to medicine and bioisosterism in drug development: a study of the discovery and development of ACE inhibitors from snake venom. Macedonian Pharmaceutical Bulletin 66:2, pages 15-33.
Crossref
Crossref
D. Dahlgren, C. Roos, P. Johansson, C. Tannergren, A. Lundqvist, P. Langguth, M. Sjöblom, E. Sjögren & H. Lennernäs. (2018) The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs. International Journal of Pharmaceutics 547:1-2, pages 158-168.
Crossref
Crossref
Roger K. Verbeeck, Isadore Kanfer, Raimar Löbenberg, Bertil Abrahamsson, Rodrigo Cristofoletti, D.W. Groot, Peter Langguth, James E. Polli, Alan Parr, Vinod P. Shah, Mehul Mehta & Jennifer B. Dressman. (2017) Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences 106:8, pages 1933-1943.
Crossref
Crossref
David Dahlgren, Carl Roos, Pernilla Johansson, Anders Lundqvist, Christer Tannergren, Bertil Abrahamsson, Erik Sjögren & Hans Lennernäs. (2016) Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms. Molecular Pharmaceutics 13:9, pages 3022-3033.
Crossref
Crossref
Vinay K. Holenarsipur, Nilesh Gaud, Jaydeep Sinha, Sankara Sivaprasad, Priyadeep Bhutani, Murali Subramanian, Sheelendra Pratap Singh, Rambabu Arla, Sundeep Paruchury, Tarun Sharma, Punit Marathe & Sandhya Mandlekar. (2015) Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharmaceutics & Drug Disposition 36:6, pages 385-397.
Crossref
Crossref
Brian C. Ferslew, Kathleen Köck, Arlene S. Bridges & Kim L. R. Brouwer. (2014) Role of Multidrug Resistance–Associated Protein 4 in the Basolateral Efflux of Hepatically Derived Enalaprilat. Drug Metabolism and Disposition 42:9, pages 1567-1574.
Crossref
Crossref
Fouad Helal & Majella E. Lane. (2014) Transdermal delivery of Angiotensin Converting Enzyme inhibitors. European Journal of Pharmaceutics and Biopharmaceutics 88:1, pages 1-7.
Crossref
Crossref
Drago R. Sliskovic. 2013. Drug Discovery. Drug Discovery
141
204
.
Alexander V. LyubimovRonald E. White. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
40
.
Donald J. AbrahamPaul W. Erhardt, Rahul Khupse, Jeffrey G. Sarver & Jill A. Trendel. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
219
288
.
Ana Cámara‐Artigas, Vicente Jara‐Pérez & Montserrat Andújar‐Sánchez. 2009. Drug Design of Zinc‐Enzyme Inhibitors. Drug Design of Zinc‐Enzyme Inhibitors
749
787
.
Sundeep S. Dhareshwar. 2007. Prodrugs. Prodrugs
1221
1229
.
Valentino J. Stella. 2007. Prodrugs. Prodrugs
37
82
.
Valentino J. Stella. 2007. Prodrugs. Prodrugs
3
33
.
Phensri Thongnopnua & Chotima Poeaknapo. (2005) High-performance liquid chromatographic determination of enalapril in human plasma by enzyme kinetic analytical method. Journal of Pharmaceutical and Biomedical Analysis 37:4, pages 763-769.
Crossref
Crossref
Thomas Unger & Bernward A. SchölkensP. Gohlke & B. A.. 2004. Angiotensin Vol. II. Angiotensin Vol. II
375
413
.
Yuan H. Zhao, Joelle Le, Michael H. Abraham, Anne Hersey, Peter J. Eddershaw, Chris N. Luscombe, Darko Boutina, Gordon Beck, Brad Sherborne, Ian Cooper & James A. Platts. (2001) Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. Journal of Pharmaceutical Sciences 90:6, pages 749-784.
Crossref
Crossref
Joel Menard & Arthur A. Patchett. 2001. Drug Discovery and Design. Drug Discovery and Design
13
75
.
Ronda K. Rippley, John Connor, Janet Boyle, Thomas E Bradstreet, Elizabeth Hand, Man‐Wai Lo & M. Gail Murphy. (2001) Pharmacokinetic assessment of an oral enalapril suspension for use in children. Biopharmaceutics & Drug Disposition 21:9, pages 339-344.
Crossref
Crossref
Valentino J. Stella. (1996) Preface. Advanced Drug Delivery Reviews 19:2, pages 111-114.
Crossref
Crossref
Bernard Testa & John Caldwell. (1998) Prodrugs revisited: The “ad hoc” approach as a complement to ligand design. Medicinal Research Reviews 16:3, pages 233-241.
Crossref
Crossref
Kathleen M. Stevenson, Karen J. Gibson & Eugenie R. Lumbers. (2012) Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep. British Journal of Pharmacology 114:7, pages 1495-1501.
Crossref
Crossref
A.Z Rónai, E Fehér, J Botyánszki, J Hepp, A Magyar & K Medzihradszky. (1995) Substrate- and inhibitor-specificity of a nonendothelial enzyme which forms [Met5]-enkephalin from [Met5]-enkephalin-Arg6, Phe7 in isolated rabbit ear artery: Pharmacological characterization. Neuropeptides 28:3, pages 137-145.
Crossref
Crossref
K KumagaiH SuzukiM RyuzakiH KumagaiM IchikawaM JimboY MatsumuraT Saruta. (1992) Effects of antihypertensive agents on arterial baroreceptor reflexes in conscious rats.. Hypertension 20:5, pages 701-709.
Crossref
Crossref
Malle Jurima-Romet & Hide S. Huang. (1992) Enalapril hepatotoxicity in the rat. Biochemical Pharmacology 44:9, pages 1803-1810.
Crossref
Crossref
J. Aken, I. Leusen, E. Lacroix, A. Somer, G. Roily & L. Calliauw. (1992) Influence of converting enzyme inhibition on isoflurane-induced hypotension for cerebral aneurysm surgery. Anaesthesia 47:3, pages 261-264.
Crossref
Crossref
Malle Jurima-Romet, Hide S. Huang, Charles J. Paul & Barry H. Thomas. (1991) Enalapril cytotoxicity in primary cultures of rat hepatocytes. I. Effects of cytochrome P450 inducers and inhibitors. Toxicology Letters 58:3, pages 257-267.
Crossref
Crossref
D. Gaudry, M. Hayes, L. Khemani, J. Miotto & D. Alkalay. (1991) Determination of CGS 16617 and stable isotope-labeled CGS 16617, an angiotensin-converting enzyme inhibitor, in human plasma by gas chromatography/mass spectrometry. Biological Mass Spectrometry 20:1, pages 26-30.
Crossref
Crossref
T. Unger, P. Gohlke & M.-G. Gruber. 1990. Pharmacology of Antihypertensive Therapeutics. Pharmacology of Antihypertensive Therapeutics
377
481
.
G. G. Skellern. (1989) RECENT ADVANCES IN PHARMACEUTICAL CHEMISTRY—ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. Journal of Clinical Pharmacy and Therapeutics 14:5, pages 341-354.
Crossref
Crossref
PE Williams, AN Brown, S Rajaguru, RJ Francis, GE Walters, J McEwen & C Durnin. (2012) The pharmacokinetics and bioavailability of cilazapril in normal man.. British Journal of Clinical Pharmacology 27:S2.
Crossref
Crossref
H. Schunkert, J. Kindler, M. Gassmann, W. Lahn, R. Irmisch, E. Ritz, E. R. Debusmann, J. O. Pujadas, K. M. Koch & H. -G. Sieberth. (1989) Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. European Journal of Clinical Pharmacology 37:3, pages 249-256.
Crossref
Crossref
D. Kandiah, W. J. Penny, A. G. Fraser & M. J. Lewis. (1988) A possible drug interaction between rifampicin and enalapril. European Journal of Clinical Pharmacology 35:4, pages 431-432.
Crossref
Crossref
Mark Borek, Shlomo Charlap & William Frishman. (1987) Enalapril: A Long-acting Angiotensin-Converting Enzyme Inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 7:5, pages 133-145.
Crossref
Crossref
K Dickstein, AE Till, T Aarsland, K Tjelta, AM Abrahamsen, K Kristianson, HJ Gomez, H Gregg & M Hichens. (2012) The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.. British Journal of Clinical Pharmacology 23:4, pages 403-410.
Crossref
Crossref
Dominic P. Ip & Gerald S. Brenner. 1987.
207
243
.
Günther Kaiser, Roland Ackermann, Walter Dieterle & Jean-Pierre Dubois. (1987) Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 419, pages 123-133.
Crossref
Crossref
Edward B. Nelson, James L. Pool & Addison A. Taylor. (1986) Pharmacology of angiotensin converting enzyme inhibitors: A review. The American Journal of Medicine 81:4, pages 13-18.
Crossref
Crossref
K Dickstein, T Aarsland, L Woie, A.M Abrahamsen, F Fyhrquist, S Cummings, H.J Gomex, E Hagen & K Kristianson. (1986) Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure. American Heart Journal 112:1, pages 121-129.
Crossref
Crossref
John D. Cleary & Jerry W. Taylor. (2016) Enalapril: A New Angiotensin Converting Enzyme Inhibitor. Drug Intelligence & Clinical Pharmacy 20:3, pages 177-186.
Crossref
Crossref
Fiona Broughton Pipkin & Carol P. Wallace. (1986) The effect of enalapril (MK421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her foetus. British Journal of Pharmacology 87:3, pages 533-542.
Crossref
Crossref
Ashok Rakhit, Margaret E. Hurley, Vijay Tipnis, Jean Coleman, Alan Rommel & Hans R. Brunner. (2013) Pharmacokinetics and Pharmacodynamics of Pentopril, a New Angiotensin‐Converting‐Enzyme Inhibitor in Humans. The Journal of Clinical Pharmacology 26:3, pages 156-164.
Crossref
Crossref
Ashok Rakhit, Gregory Kochak, Ronald Dotson & Vijay Tipnis. (1985) Disposition of Pentopril, a New Orally Active Angiotensin-Converting Enzyme Inhibitor, and Its Active Metabolite in Rats. Journal of Pharmaceutical Sciences 74:9, pages 947-952.
Crossref
Crossref
Ashok Rakhit, Margaret E. Hurley, Elliot Redalieu, Gregory Kochak, Vijay Tipnis, Jean Coleman & Alan Rommel. (2013) Effect of Food on the Bioavailability of Pentopril, an Angiotensin‐Converting‐Enzyme Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology 25:6, pages 424-428.
Crossref
Crossref
M Hiwatari, P L Nolan & C I Johnston. (1985) The contribution of vasopressin and angiotensin to the maintenance of blood pressure after autonomic blockade.. Hypertension 7:4, pages 547-553.
Crossref
Crossref
Louis J RileyJr.Jr., Peter H Vlasses & Roger K Ferguson. (1985) Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor, enalapril. American Heart Journal 109:5, pages 1085-1089.
Crossref
Crossref
V. Tipnis & A. Rakhit. (1985) Determination of pentopril, an angiotensin converting enzyme inhibitor, and its active metabolite in urine. Journal of Chromatography B: Biomedical Sciences and Applications 345, pages 396-401.
Crossref
Crossref
Valentino J. Stella & Kenneth J. Himmelstein. 1985. Directed Drug Delivery. Directed Drug Delivery
247
267
.
Alice E. Till, Hector J. Gomez, Martin Hichens, James A. Bolognese, W. R. McNabb, B. A. Brooks, F. Noormohamed & A. F. Lant. (2006) Pharmacokinetics of repeated single oral doses of enalapril maleate (mk‐421) in normal volunteers. Biopharmaceutics & Drug Disposition 5:3, pages 273-280.
Crossref
Crossref
RO Davies, HJ Gomez, JD Irvin & JF Walker. (2012) An overview of the clinical pharmacology of enalapril.. British Journal of Clinical Pharmacology 18:S2.
Crossref
Crossref
Charles S. Sweet & Edgar H. Ulm. (2007) Enalapril. Cardiovascular Drug Reviews 2:1, pages 1-17.
Crossref
Crossref
P. U. Witte, R. Irmisch, P. Hajd� & H. Metzger. (1984) Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. European Journal of Clinical Pharmacology 27:5, pages 577-581.
Crossref
Crossref